Dr. Albert Bourla leads Pfizer in its purpose: Breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.

During his more than 25 years at Pfizer, he has held several senior global positions across a range of markets and disciplines. Before becoming CEO, he served as COO, overseeing commercial strategy, manufacturing, and global product development.

Previously, he served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. He also created the Patient and Health Impact group, dedicated to increasing patient access, demonstrating the value of Pfizer’s medicines, and broader business model innovation. Prior to that, he was president and General Manager of the Established Products business.

Albert is a Doctor of Veterinary Medicine with a Ph.D. from the Veterinary School of Aristotle University and began his Pfizer career in 1993 in the Animal Health division. In 2020, he was ranked America’s top CEO in the pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of the Partnership for New York City, a vice president of the IFPMA, a trustee of the US Council for International Business, and a director on multiple boards, including Pfizer Inc., the Pfizer Foundation, PhRMA, and Catalyst.